BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Votoplam readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Votoplam\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06254482-11257@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Votoplam: Phase 2 readout est. (NCT06254482)
DESCRIPTION:Votoplam\, phase 2\, Huntington's Disease.\nStudy: An Extension
  Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Partic
 ipants With Huntington's Disease (HD)\nEstimated primary completion: 16 Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0625448
 2
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326709-11257@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Votoplam: Phase 3 readout est. (NCT07326709)
DESCRIPTION:Votoplam\, phase 3\, Huntington's Disease.\nStudy: A Study to I
 nvestigate the Efficacy\, Safety and Tolerability of Votoplam in Participa
 nts With Huntington's Disease\nEstimated primary completion: 2 April 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07326709
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
